PCSK9 and diabetes mellitus: While in patients with DM the current guidelines’ recommendations for LDLc lowering, while preventing CV events, include a high-intensity statin therapy wherever possible, with multiple options of intensification or alternatives such as ezetimibe, bempedoic acid, and monoclonal antibodies that inhibit PCSK9 or siRNA such as inclisiran for the management of dyslipidaemia in patients with prediabetes, more future studies that would lead to specific recommendations are needed.